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Background: There are no approved medications for juvenile fibromyalgia (JFM), a disorder that is often under-
diagnosed. The effects of milnacipran, a drug approved for the management of fibromyalgia (FM) in adults, was
assessed in a clinical trial program for JFM.
Methods: Patients, ages 13–17 years who met the Yunus and Masi criteria for JFM and/or 1990 American College of
Rheumatology criteria for FM, were enrolled in a responder-enriched, randomized withdrawal trial. After receiving
open-label milnacipran (8 weeks), patients with ≥50 % improvement in pain underwent double-blind randomization
(1:2) to either placebo or continuing treatment with milnacipran (8 weeks). All patients, including those who did not
meet the randomization criteria for double-blind withdrawal, were allowed to enter an extension study with open-label
milnacipran (up to 52 weeks). The primary endpoint was loss of therapeutic response (LTR) during the double-blind
period. Additional outcome measures included the Patient Global Impression of Severity (PGIS), Pediatric Quality of Life
Inventory (PedsQL: Generic Core Scales, Multidimensional Fatigue Scale), and Multidimensional Anxiety Scale for
Children (MASC). Safety assessments included adverse events (AEs), vital signs, electrocardiograms, and laboratory tests.
Results: The milnacipran program was terminated early due to low enrollment. Because only 20 patients were
randomized into the double-blind withdrawal period, statistical analyses were not conducted for the LTR endpoint.
However, 116 patients entered the open-label period of the initial study and 57 participated in the open-label extension
study. Their experience provides preliminary information about the use of milnacipran in JFM patients. During both open-
label periods, there were mean improvements in pain severity, PGIC, PedsQL, and MASC scores. No unexpected safety
issues were detected. The most commonly reported treatment-emergent AEs were nausea, headache, vomiting, and
dizziness. Mean increases in heart rate and blood pressure were observed, and were consistent with the AE profile in
adults with FM.
Conclusions: The open-label findings provide preliminary evidence that milnacipran may improve symptoms of JFM,
with a safety and tolerability profile that is consistent with the experience in adult FM patients. Future trial designs
for JFM should consider the relatively low recognition of this condition compared to adult FM and the difficulties
with enrollment.
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Juvenile fibromyalgia (JFM) is a chronic pain disorder
that affects an estimated 1.2 % to 6.2 % of children and
adolescents in the general population, more frequently
in girls than boys [1–3]. JFM accounts for an estimated
7 % to 15 % of referrals to pediatric rheumatology clinics
[4] and has been found in 52 % of female adolescents
who were admitted for inpatient psychiatric treatment
[5]. Recognizing this disorder can be challenging, and
patients may consult with several different clinicians be-
fore receiving a diagnosis of JFM [4]. JFM can be identi-
fied based on a number of characteristic symptoms,
including diffuse and chronic musculoskeletal pain,
fatigue, sleep difficulties, headaches, anxiety, and
depressed mood [2]. In clinical studies, diagnosis is usu-
ally based on the Yunus and Masi criteria for JFM [6] or
the 1990 American College of Rheumatology (ACR)
fibromyalgia (FM) criteria for adults [7].
As with adult FM, it has been hypothesized that JFM
involves abnormal pain processing in the central nervous
system, which results in hypersensitivity to painful and
nonpainful stimuli [4]. The symptoms and prognosis for
the disorder may also be affected by factors such as
family and peer relationships, emotional and social func-
tioning, and the presence of anxiety or mood disorders
(lifetime or current) [8–10]. Given the multisymptomatic
nature of JFM, along with the complex neurobiological
and psychosocial components, an individualized and
multidisciplinary treatment approach is generally recom-
mended [2]. Cognitive behavioral therapy (CBT) may
help patients change their perceptions about pain and
develop coping skills to navigate the challenges of JFM
[11]. In adolescents with JFM, this therapeutic approach
has been shown to improve pain coping and functional
ability [12–16]. Exercise programs may also provide
therapeutic benefits, such as increased physical activity
and improved quality of life [17, 18].
No medications have been approved for the management
of JFM, although results from a preliminary trial of fluoxet-
ine in JFM have been published [19]. Three medications are
currently approved for the management of FM in adults: an
alpha-2-delta ligand, pregabalin, which may modulate pain
by decreasing neurotransmission of glutamate and sub-
stance P; and 2 serotonin and norepinephrine reuptake in-
hibitors, duloxetine and milnacipran, which may target the
descending central neural pathways involved in pain inhib-
ition [20]. In placebo-controlled trials with adult FM
patients, all 3 medications demonstrated statistically signifi-
cant improvements in pain, function, and global assessment
of improvement. Pregabalin, duloxetine, and milnacipran
have also been shown to have positive effects on secondary
symptom domains of FM. For example, duloxetine and mil-
nacipran were shown to be effective for fatigue and depres-
sive symptoms [21–23], milnacipran for self-reportedcognitive difficulties [24, 25], and pregabalin for sleep dis-
turbances [26, 27]. These various effects in adult FM pa-
tients are consistent with pharmacologic differences among
the medications, including the greater effect of milnacipran
on norepinephrine reuptake relative to duloxetine [28].
These differences are also reflected in the side-effect pro-
files of the medications [29–31]. Patients with FM are a het-
erogeneous group and multiple treatment options are
important to address the variability of symptoms and im-
pact of FM [32].
A clinical trial of pregabalin in JFM was recently
completed (NCT01020474), the results of which are cur-
rently being analyzed and are as yet unpublished [33]; a
JFM study with duloxetine is ongoing (NCT01237587). The
JFM clinical trial program with milnacipran consisted of a
responder-enriched, randomized withdrawal study (NCT0
1328002 [MLN-MD-14]) followed by an open-label exten-
sion study (NCT01331109 [MLN-MD-29]). This program,
described in the current report, was terminated early be-
cause of difficulties recruiting an adequate number of pa-
tients who had been diagnosed with JFM and met the study
criteria. However, demographic data obtained on a com-
paratively large group of patients with JFM (n = 116), along
with safety and preliminary findings on outcome measures,
may provide important contemporary characterizations of
these patients and be helpful in designing future JFM trials.
Methods
Program overview
The milnacipran program for JFM was conducted at 47
study sites in the United States. Patients who met the en-
rollment criteria entered the open-label period of the ran-
domized withdrawal study and were treated with
milnacipran (up to 100 mg/day in divided doses). Re-
sponders, as defined by stringent pre-defined criteria
(described below), were then randomized to continue mil-
nacipran or switch to placebo. Patients who were random-
ized and entered the double-blind withdrawal period,
those who did not meet randomization criteria, and those
who dropped out for reasons other than tolerability or ad-
verse effects, were permitted to enter the open-label ex-
tension study (Fig. 1). Both studies were conducted in full
compliance with the US Food and Drug Administration
guidelines for good clinical practice and in accordance
with Declaration of Helsinki principles. Approvals were
obtained from all Institutional Review Boards prior to the
start of the study. Written assent from each patient and
written consent from his or her parent, legal guardian, or
other legal representative were also obtained.
Randomized withdrawal study
Eligibility criteria
Male or female outpatients, 13 to 17 years of age with a
diagnosis of FM based on Yunus and Masi criteria [6]
Fig. 1 Study flow. *Reasons for ineligibility occurring in >1 patient: current severe psychiatric illness (12 patients); did not have a mean daily pain
rating of ≥3 to≤ 9 in the week prior to the baseline visit (8 patients); did not meet Yunus and Masi criteria or ACR criteria (6 patients); had
positive drug screen for illegal substances (4 patients); unwilling, unable, or inadvisable to discontinue prohibited medications during washout
(3 patients). DB = double blind, ITT = intent to treat, OL = open label
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this study. Patients were also required to have an
average pain score of 3 to 9 at screening and previous
unsatisfactory response to a nonpharmacologic FMtreatment. Pain scores were defined as the 1-week
average of daily pain ratings on an 11-point scale that
ranged from 0 (“no pain”) to 10 (“pain as bad as you
can imagine”).
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current severe psychiatric illness as determined by the In-
vestigator or based on responses to the Mini International
Neuropsychiatric Interview for Children and Adolescents
(MINI-KID [34]). Patients with significant risk of suicidal-
ity were also excluded based on the Investigator’s judg-
ment and review of the following: patient and guardian
responses to the MINI-KID; suicidal ideation (levels 3, 4,
or 5) or any suicidal behavior within the past 6 months,
as reported using the electronic Columbia–Suicide Sever-
ity Rating Scale (C-SSRS) [35]. Other key exclusion cri-
teria included: active liver disease or severe renal
impairment; history of seizure disorder other than febrile
seizures; any psychiatric or medical condition that could
interfere with study conduct, confound the interpretation
of study results, or endanger the patient’s well-being. Pro-
hibited medications included any centrally acting phar-
macotherapies commonly used to treat FM. Washout of
these medications was required prior to entering the
study. Nonpharmacologic therapies (e.g., physical therapy,
acupuncture, chiropractic manipulation, CBT or other
psychotherapy, biofeedback) were allowed provided that
the treatments were initiated >30 days prior to screening
and continued without major change during the studies.
A more detailed list of eligibility criteria is provided in
Additional file 1: Table S1.
Study conduct
Patients taking prohibited medications were washed out
for up to 4 weeks before entering the 8-week open-label
period of the randomized withdrawal study. During the
first 4 weeks of this open-label period, milnacipran doses
were escalated to 100 mg/day if tolerated. The dosing regi-
men was as follows: 12.5 mg on the first day; 12.5 mg
twice daily (BID) for days 2 to 7; 25 mg BID for days 8 to
14; 37.5 mg BID for days 15 to 21; and 50 mg BID for days
22 to 28. Patients who could not tolerate the minimum
dose of 50 mg/day were discontinued from the study.
Those who tolerated at least the minimum dose then re-
ceived 4 weeks of open-label milnacipran at the maximum
tolerated stable dose (MTD; 50, 75, or 100 mg/day).
At the conclusion of the 8-week open-label treatment
period, patients with ≥50 % pain improvement from
baseline were considered eligible for double-blind
randomization. Patients who met the ≥50 % pain im-
provement criterion were randomized (2:1) to milnaci-
pran or placebo (i.e., continue treatment at the MTD or
discontinue treatment, respectively). Patients with <50 %
pain improvement after the open-label period were not
randomized to the double-blind withdrawal period.
However, these patients were permitted to enroll directly
into the extension study. After completing or discon-
tinuing prematurely from the randomized withdrawal
study, patients who did not want to participate in theextension study were entered into a 1-week down-
titration period.
Extension study
Patients were allowed to enter the extension study if
they had participated in the double-blind withdrawal
study and tolerated the minimum dose of 50 mg/day.
Premature discontinuation from the lead-in study (un-
less due to an adverse effect of the medication) was not
a reason for exclusion. As described previously for the
open-label period of the randomized withdrawal study,
patients in the extension study underwent dose escal-
ation for up to 4 weeks until they reached the MTD.
They then continued to receive milnacipran at the MTD
for up to 48 weeks. Those unable to tolerate the mini-
mum dose of 50 mg/day were discontinued from the ex-
tension study and entered into a 1-week down-titration
period.
Outcome measures
A timeline of study assessments is presented in
Additional file 1: Table S2. For the open-label period of
the randomized withdrawal study, mean changes from
baseline to end of treatment (i.e., last available assess-
ment in the open-label period for each patient) were
assessed in the following measures: 1-week average pain
severity rating, calculated from daily pain ratings that
were recorded by patients once-daily every morning
using an interactive voice response and/or web response
system; Patient Global Impression of Severity (PGIS),
Pediatric Quality of Life Inventory-Teen Report (PedsQL
[36]), and the Multidimensional Anxiety Scale for Chil-
dren (MASC [37]). Although the Children’s Depression
Inventory (CDI [38]) was primarily used as a safety as-
sessment to monitor changes in depressive symptoms,
mean changes in CDI total score are shown with out-
come results in this report.
The PGIS consisted of a single question (“Considering
all aspects of your illness, how do you evaluate the se-
verity of your fibromyalgia?”) with scores ranging from 1
(“normal, not at all ill”) to 7 (“extremely ill”). The
PedsQL, which has been validated in children and ado-
lescents with FM [36], includes the following assess-
ments: the 23-item Generic Core Scales, which covers
physical, emotional, social, and school functioning; and
the 18-item Multidimensional Fatigue Scale, which
covers general fatigue, sleep/rest, and cognitive fatigue.
Raw scores for the PedsQL were reversed and trans-
formed to a 0–100 scale, with higher scores indicating
better quality of life. The MASC is a 39-item assessment
that evaluates physical symptoms, social anxiety, harm
avoidance, and separation/panic anxiety. The CDI is a
27-item instrument that assesses the existence and se-
verity of depressive symptoms in the following areas:
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anhedonia, appetite, and interpersonal problems. Higher
total scores indicate greater symptom severity for both
the MASC (range, 0 to 117) and CDI (range, 0 to 54).
For the double-blind period of the randomized with-
drawal study, the primary endpoint was time to loss of
therapeutic response (LTR) from randomization to end
of double-blind treatment. LTR was defined as any of
the following events: worsening of JFM requiring alter-
nate treatment; increase in pain score to >70 % of base-
line; or withdrawal from the study for an adverse event
(AE). In order to determine LTR, Investigators reviewed
patients’ daily pain ratings at each study visit. They also
assessed whether patients’ responses to the current
treatment were sufficiently inadequate (based on wors-
ening of JFM symptoms and/or lack of tolerability) to
justify discontinuing the current treatment and imple-
menting an alternate treatment; the type of alternate
treatment was left to the Investigator’s discretion. Sec-
ondary endpoints were the mean score changes from
randomization to end of double-blind treatment in pain,
PGIS, PedsQL (Generic Core Scales, Multidimensional
Fatigue Scale), and MASC.
Outcomes in the open-label extension study were eval-
uated based on mean score changes from baseline of the
randomized withdrawal study to end of treatment (i.e.,
last available assessment for pain, PGIS, PedsQL, MASC,
or CDI in each patient). The interactive web/voice re-
sponse system was not used to collect pain data in the
extension study; instead, the 11-point pain scale (range,
0–10) was administered at all study visits to assess each
patient’s average pain over the past week.Safety measures
Safety and tolerability assessments included AE report-
ing, vital signs (sitting blood pressure, sitting heart rate,
and body weight), electrocardiogram readings, and clin-
ical laboratory tests. Changes in depressive and other
psychiatric symptoms, as well as suicidal ideation and
behavior, were monitored using the CDI and C-SSRS.
In the randomized withdrawal study, treatment-
emergent AEs (TEAEs) for each period were defined as
AEs that began or increased in severity after the first treat-
ment dose of that period or within 30 days after the last
dose of that period (in patients who discontinued or com-
pleted treatment). In the extension study, TEAEs were de-
fined as AEs that started after the first dose of open-label
treatment in the randomized withdrawal study or were
present before this dose but increased in severity during
the extension study. Newly emergent AEs (NEAEs) in the
extension study were defined as AEs that occurred after
the first dose of extension study treatment or increased in
severity during the extension study.Mean changes in vital signs, electrocardiograms, and
laboratory tests, as well as the percentage of individual
patients with potentially clinically significant (PCS)
changes in these parameters, were analyzed for each
study.
Statistical analyses
In the randomized withdrawal study, the open-label
safety and intent-to-treat (ITT) populations included
screened patients who received ≥1 dose of open-label
study medication. The double-blind safety and ITT pop-
ulations included all randomized patients who took ≥1
dose of double-blind study medication. In the open-label
extension study, the safety and ITT populations included
screened patients who received ≥1 dose extension study
medication.
The primary efficacy parameter in the initial study was
time to first LTR. Based on the available literature for
milnacipran in adult FM [22, 24, 25] and assuming LTR
rates of 60 % for placebo and 35 % for milnacipran, it
was estimated that 156 patients (placebo, 52; milnaci-
pran, 104) would be needed to detect the above
treatment difference with a power of 80 % or higher at
the 2-sided 5 % significance level test. Assuming a com-
pleter/responder rate of approximately 50 %, it was esti-
mated that 312 patients would need to participate in the
open-label treatment period. The extension study was a
follow-up to the randomized withdrawal study; there-
fore, sample size was not based on statistical consider-
ations. However, due to unexpected low enrollment and
early termination of the studies, all efficacy and safety
outcomes were analyzed descriptively.
Results
Patients
Of 171 screened patients, 116 met the eligibility criteria
and entered the open-label period of the randomized
withdrawal study; all of these patients received ≥1 dose
of open-label treatment and were included in the safety
and ITT populations (Fig. 1). In this open-label popula-
tion, 96 (82.8 %) patients were diagnosed with FM based
on both the Yunus and Masi criteria and the 1990 ACR
criteria; 19 (16.4 %) patients met only the Yunus and
Masi criteria and 1 patient (0.9 %) met only the ACR cri-
teria (Table 1). The majority of patients were female
(84.5 % [98/116]) and white (86.2 % [100/116]), with a
mean age of 15.6 years (Table 2). Patients commonly
reported history of headache (34.5 %), migraine (22.4 %),
insomnia (17.2 %), depressive symptoms (16.4 %), gas-
troesophageal reflux disease (14.7 %), back pain (12.1 %),
and dysmenorrhea (12.1 %) (Table 1).
All 20 patients who met the criteria for randomization
received ≥1 dose of double-blind treatment and were in-
cluded in the safety and ITT populations (Fig. 1). Two
Table 1 Medical and psychiatric history in patients entering the
open-label period of the randomized withdrawal study
Patients
N = 116
Fibromyalgia diagnosis, n (%)
Yunus and Masi criteria only 19 (16.4)
1990 ACR criteria only 1 (0.9)
Both criteria 96 (82.8)




Attention deficit/hyperactivity disorder 8 (6.9)
Sleep disorder 5 (4.3)
Lifetime suicidality, n (%)
Suicidal ideation 24 (20.7)
Suicidal behavior 4 (3.4)
Pain disorders or symptoms, n (%)a
Headache 40 (34.5)
Migraine 26 (22.4)
Gastroesophageal reflux disease 17 (14.7)
Back pain 14 (12.1)
Dysmenorrhea 14 (12.1)
Irritable bowel syndrome 8 (6.9)
Arthralgia 7 (6.0)
Fatigue 6 (5.2)
Restless leg syndrome 5 (4.3)
Abdominal pain 4 (3.4)
Hypermobility syndrome 4 (3.4)
Abdominal pain upper 3 (2.6)
Myalgiab 3 (2.6)
Raynaud’s phenomenon 3 (2.6)
Temporomandibular joint syndrome 3 (2.6)
Other medical symptoms or conditions, n (%)c
Asthma 27 (23.3)
Drug hypersensitivity 21 (18.1)
Seasonal allergy 19 (16.4)
Tonsillectomy 18 (15.5)
aIncludes MedDRA preferred terms related to symptoms or disorders that have
been associated with fibromyalgia. Additional terms of potential interest that
were reported in 1 patient each: bipolar disorder, carpal tunnel syndrome,
chronic fatigue syndrome, dysthymic disorder, juvenile arthritis, major
depression, obsessive-compulsive disorder, osteoarthritis, osteochondrosis,
panic attack, post-traumatic stress disorder, psychotic disorder, seasonal
affective disorder, social phobia, spinal osteoarthritis, tendonitis, tic; scoliosis
was reported in 5 patients
bDoes not include symptoms that would be classified under the MedDRA
preferred term of “fibromyalgia”
cIncludes all other MedDRA preferred terms that were reported in ≥10 % of
the open-label population
ACR = American College of Rheumatology





Nonrandomized Randomized All patients
n = 96 n = 20 n = 57
Age, years, mean (SD) 15.7 (1.3) 15.0 (1.6) 15.4 (1.4)
Female, n (%) 86 (89.6) 12 (60.0) 50 (87.7)
White, n (%) 86 (89.6) 14 (70.0) 51 (89.5)
BMI, kg/m2, mean (SD) 25.8 (6.2) 24.8 (5.3) 26.1 (6.3)
Maximum tolerated
dosea
50 mg/day 6 (6.3) 1 (7.1)a 3 (5.3)
75 mg/day 9 (9.4) 4 (28.6)a 8 (14.0)
100 mg/day 69 (71.9) 9 (64.3)a 46 (80.7)
No available MTD data 12 (12.5) 0a 0
aAs reported in the milnacipran group only (n = 14)
BMI = body mass index, MTD = maximum tolerated dose, SD = standard deviation
MTD = maximum tolerated dose
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double-blind randomized withdrawal period: 1 due to an
AE, and 1 due to insufficient therapeutic response. A
total of 57 patients (44 from the open-label population,
13 from the double-blind population) entered the exten-
sion study, all of whom were included in the safety and
ITT populations. The extension study outcomes pre-
sented in this report are from patients who had avail-
able post-baseline assessments (i.e., n = 56 at Visit 2
[Week 4] of the extension study).
Based on available data, the majority of patients in
both the randomized withdrawal study and the extension
study had an MTD of 100 mg/day (Table 2). The mean
treatment duration for the open-label period of the ran-
domized withdrawal study was 52.3 days in nonrando-
mized patients and 56.8 days in patients who were
subsequently randomized to double-blind treatment.
The mean duration of double-blind treatment was
53.0 days. In the extension study, the mean duration of
treatment was 143.6 days, with minimum and maximum
durations of 8 and 370 days, respectively.
Outcome measures
Randomized withdrawal study
At the end of open-label treatment with milnacipran in
the randomized withdrawal study, mean improvements
were found in pain, global disease severity, quality of life,
and fatigue symptoms (Table 3). Patients with severe
psychiatric comorbidities were excluded from the study,
but mean changes on the MASC and CDI indicated no
worsening of anxiety or depressive symptoms during this
period. As expected, all mean score changes were greater
in patients who met the pain criterion for randomization
(i.e., ≥50 % decrease in pain severity from open-label
Table 3 Mean changes from baseline in the open-label period of the randomized withdrawal study
Nonrandomized Randomized
n = 96 n = 20
Measures, mean (SD) Baseline Changea Baseline Changea
Pain, range 0-10 6.5 (1.4) −1.1 (1.6) 6.1 (1.3) −3.3 (1.0)
PGIS, range 1-7 4.0 (0.8) −0.4 (1.0) 4.0 (0.8) −1.0 (1.0)
PedsQL-Generic Core Scales, range 0-100 55.6 (14.8) 4.5 (13.0) 54.2 (11.4) 10.9 (10.9)
PedsQL-Multidimensional Fatigue Scale, range 0-100 46.1 (17.6) 5.8 (15.3) 41.3 (13.3) 13.3 (12.1)
MASC, range 0-117 45.1 (16.5) −2.4 (12.2) 46.1 (13.4) −5.4 (13.2)
CDI, range 0-54b 11.9 (7.1) −1.2 (5.0) 11.1 (5.5) −2.4 (4.9)
aChanges are based on end-of-treatment values. Negative changes represent mean improvements in pain, PGIS, MASC, and CDI scores; positive values represent
mean improvements in PedsQL scores. For pain, data were based on electronic entries from Week 7 (i.e., the last week prior to randomization). For other
measures, data were based on last available open-label assessments, including those from patients who prematurely discontinued the study
bPrimarily used in this study as a safety assessment to monitor changes in depressive symptoms
CDI = Children’s Depression Inventory, MASC =Multidimensional Anxiety Scale, PGIS = Patient Global Impression of Severity, PedsQL = Pediatric Quality of Life
Inventory-Teen Report, SD = standard deviation
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lysis of pain data from the nonrandomized population
showed that although these patients did not meet the
≥50 % responder criterion after open-label milnacipran
treatment, 27.7 % of them did experience a ≥30 % de-
crease in pain severity, which has been defined as a
threshold of clinically relevant improvement in adult FM
patients [39].
Only 20 patients were eligible for randomization into
the double-blind period. An LTR due to worsening of
FM requiring alternative treatment was detected in 2 pa-
tients from the milnacipran group; time to LTR was
6 days in 1 patient, 8 days in the other. Slight worsening
in PGIS, PedsQL, and MASC scores were found in both
the placebo and milnacipran groups.
Extension study
During the extension study, continued mean improve-
ments from the lead-in study baseline in pain
scores—and to a lesser extent, in the PedsQL Generic
Core Scales, MASC, and CDI scores—were observed by
Week 4 (i.e., end of dose escalation to MTD in the ex-
tension study) and at subsequent study visits (Fig. 2). A
post hoc analysis of pain data from this study showed
that at Week 20, the last time point at which >50 % of
entering patients were still participating in the study (n
= 35), 65.7 % of patients had ≥30 % pain improvement
from the beginning of the prior randomized withdrawal
study (Additional file 1: Figure S1). No mean worsening
of depressive symptoms were detected in patients who
participated in the extension study.
Safety
Adverse events
No serious AEs were reported during the open-label
period of the randomized withdrawal study. During the
double-blind period, 1 patient randomized to milnacipranhad a serious AE of suicidal ideation, along with a nonseri-
ous AE of anxiety, and was discontinued from the study
for these reasons. One patient from the extension study,
who had already discontinued milnacipran treatment due
to nausea, experienced suicidal ideation 45 days after the
last dose of study drug. This patient was not considered
on-therapy at the time of suicidal ideation, and this event
was judged by the Investigator as unrelated to treatment.
Another patient in the extension study had a serious AE
of cholecystitis and successfully underwent a cholecystec-
tomy. Milnacipran was suspended for 11 days; treatment
was resumed after the patient was discharged from the
hospital. No deaths occurred during the randomized with-
drawal study or the extension study.
Eight patients discontinued the open-label treatment
period of the initial study due to an AE. Four of these
patients reported nausea, which was the only AE that
led to discontinuation in >1 patient. Aside from the pa-
tient who discontinued due to the serious AE of suicidal
ideation (described above), no other patients discontin-
ued the double-blind period due to an AE. TEAEs oc-
curred more frequently during the open-label period
(78.4 % [91/116]) than in the double-blind period
(50.0 % [10/20]) (Table 4). TEAEs that occurred in
>10 % of patients during the open-label period were
nausea (32.8 %), vomiting (13.8 %), and headache
(10.3 %).
In the extension study, 10.5 % of patients discontinued
due to an AE. The percentage of patients with any TEAE
or NEAE was 73.7 % and 64.9 %, respectively. TEAEs
that were reported in >10 % of patients in the extension
study were nausea (17.5 %), tachycardia (10.5 %), and de-
creased appetite (10.5 %); these were considered to be
NEAEs in 8.8 %, 3.5 %, and 3.5 % of patients, respect-
ively (Additional file 1: Figure S2). In both studies, most
patients had TEAEs that were categorized as either mild
or moderate in severity (open-label period, 96.7 %;
Fig. 2 (See legend on next page.)
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Fig. 2 Mean changes from baseline in outcome measures during the extension study. Baseline was defined as pre-treatment values (i.e., patients’
scores prior to receiving the first dose of milnacipran in the open-label period of the randomized withdrawal study). For each visit in the extension
study, baseline only includes pre-treatment values for those patients who completed that particular study visit. The n-values represent numbers of
patients with valid assessments at baseline and at each extension study visit; graph only includes study visits that had >1 patient. *CDI was primarily
used as a safety outcome. CDI = Children’s Depression Inventory, MASC =Multidimensional Anxiety Scale for Children, PedsQL = Pediatric Quality of Life
Inventory, PGIS = Patient Global Impression of Severity






Milnacipran Placebo Milnacipran Milnacipran
Patients, n (%) n = 116 n = 6 n = 14 N = 57
Any TEAEa 91 (78.4) 4 (66.7) 6 (42.9) 42 (73.7)
Nausea 38 (32.8) 0 0 10 (17.5)
Vomiting 16 (13.8) 0 0 5 (8.8)
Headache 12 (10.3) 1 (16.7) 0 4 (7.0)
Dizziness 10 (8.6) 0 0 3 (5.3)
Fatigue 7 (6.0) 0 0 1 (1.8)
Hot flush 7 (6.0) 0 0 2 (3.5)
Tachycardiab 7 (6.0) 0 1 (7.1) 6 (10.5)
Decreased appetite 5 (4.3) 0 0 6 (10.5)
Hyperhidrosis 5 (4.3) 0 0 1 (1.8)
Insomnia 5 (4.3) 0 0 1 (1.8)
Upper respiratory tract
infection
5 (4.3) 0 1 (7.1) 0
Urinary tract infection 5 (4.3) 0 0 5 (8.8)
Abdominal pain 4 (3.4) 0 0 4 (7.0)
Gastroenteritis 4 (3.4) 0 0 1 (1.8)
Heart rate increasedb 4 (3.4) 0 0 4 (7.0)
Nasopharyngitis 4 (3.4) 0 0 2 (3.5)
Diarrhea 3 (2.6) 0 0 1 (1.8)
Dysmenorrhea 3 (2.6) 0 0 0
Irritability 3 (2.6) 0 0 0
Palpitations 3 (2.6) 0 0 1 (1.8)
Rash 3 (2.6) 0 0 0
Tremor 3 (2.6) 0 0 1 (1.8)
aReported in ≥2 % of patients during the open-label period of the randomized
withdrawal study; coded by MedDRA preferred term
bTachycardia refers to an increase in heart rate that is greater than the age-
corrected upper limit of normal. Heart rate increased refers to any increase,
whether or not within the normal age-corrected range
TEAE = treatment-emergent adverse event
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92.9 %).
Vital signs
At the end of open-label treatment in the randomized
withdrawal study, mean increases from baseline were
found in sitting blood pressure (4 to 5 mm Hg) and sit-
ting heart rate (10 bpm) (Table 5). At least once during
this period, 6.9 % of the 116 patients met the PCS cri-
teria for elevated systolic blood pressure (≥130 mm Hg
with an increase from baseline of ≥20 mm Hg) and
9.5 % met the criteria for elevated diastolic blood pres-
sure (≥80 mm Hg with increase ≥20 mm Hg); 9.5 % met
the PCS criteria for elevated heart rate (≥110 bpm with
increase of ≥30 bpm) (Additional file 1: Table S3). Dur-
ing the double-blind period, no PCS criteria were found
in >1 patient in either treatment group.
Additional increases in sitting blood pressure and
heart rate were not apparent with longer treatment dur-
ation. Among the 57 patients who entered the extension
study and were included in safety analyses, mean in-
creases from baseline of the prior randomized with-
drawal study were 3 to 4 mm Hg for blood pressure and
4 bpm for heart rate (Table 5). During the open-label
extension study, PCS criteria for elevated systolic and
diastolic blood pressure were detected in 10.9 % and
12.7 % of patients, respectively; PCS criteria for elevated
heart rate were detected in 12.7 % of patients
(Additional file 1: Table S3).
Patients receiving milnacipran had slight (<1 kg) mean
decreases in body weight after 8 weeks of open-label treat-
ment in the randomized withdrawal study (mean −0.8 kg;
range, −5.2 to +5.9 kg) and also in the extension study
(mean, −0.5 kg; range, −9.6 to +7.7 kg) (Table 5). The per-
centage of patients meeting PCS criteria for weight change
in the randomized withdrawal study or the extension
study are reported in Additional file 1: Table S3.
Electrocardiograms
An increased heart rate (≥20 bpm) was found in 37.5 % of
patients in the open-label period of the randomized with-
drawal study and 33.3 % of patients in the extension study
(Additional file 1: Table S3). A total of 14 milnacipran-
treated patients had a QRS interval ≥100 msec: 6 during
the open-label period of the randomized withdrawal study,
7 during the extension study, and 1 during both studies.



















Systolic BP, mm Hg
Baselinea 113.3 (9.7) 117.3 (7.9) 115.0 (7.7) 112.5 (8.7)
Change 4.1 (8.9) −1.2 (6.8) −1.4 (10.9) 2.5 (10.7)
Diastolic BP, mm Hg
Baselinea 69.5 (7.8) 76.3 (9.3) 70.8 (10.4) 68.1 (8.7)
Change 5.2 (8.6) −7.0 (8.3) −0.1 (9.9) 4.2 (8.8)
Heart rate, bpm
Baselinea 81.0 (11.1) 100.5 (17.9) 87.1 (17.5) 81.6 (10.8)
Change 10.0 (14.4) −6.8 (16.0) 0.1 (18.6) 4.3 (11.1)
Body weight, kg
Baselinea 69.4 (17.6) 71.9 (20.7) 64.7 (14.2) 68.9 (18.1)
Change −0.8 (2.0) 1.9 (1.7) −0.1 (1.9) −0.5 (3.9)
aFor the open-label period of the randomized withdrawal study and for the extension study, baseline was defined as the last available assessment before the first
dose of open-label treatment in the randomized withdrawal study. For the double-blind period, baseline was defined as the last available assessment prior to the
first dose of double-blind treatment
BP = blood pressure
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of milnacipran-treated patients had a QTcB >450 msec in
either study. However, no patient had an elevated QTcF of
clinical significance.
Laboratory tests
For each laboratory test, 2 or fewer milnacipran-treated
patients had a PCS value during either study (Additional
file 1: Table S4).
Discussion
Although it was important to evaluate the effects of an
approved FM medication in adolescents, designing and
conducting an appropriate clinical trial proved to be
challenging. The responder-enriched, randomized with-
drawal design used for the initial study was chosen in
anticipation of the practical difficulties—and potentially
ethical problem—of recruiting pediatric patients with a
chronic pain condition into a more conventional
placebo-controlled trial in which some participants
would not receive active treatment. The milnacipran
program allowed all eligible patients to receive at least
8 weeks of open-label milnacipran at their MTD. De-
creases in dosing were also allowed to improve tolerabil-
ity and retention. Moreover, patients were allowed to
continue receiving long-term open-label treatment with
milnacipran in the subsequent extension study even if
they did not meet the pain response criterion (i.e., ≥50 %improvement from baseline) required for entry into the
double-blind randomized withdrawal period. One draw-
back of the withdrawal study design was that a large
number of patients was needed for the open-label period
in order to evaluate efficacy (i.e., time to LTR in ≥50 %
pain responders) with any statistical certainty. Although
this was the same responder criterion used in random-
ized withdrawal studies of adult FM with both pregaba-
lin [40] and milnacipran [41], a post hoc analysis of data
from the milnacipran trial suggests that a less stringent
cutoff (e.g., ≥30 % pain improvement) may have been ad-
equate for evaluating loss of efficacy after treatment
withdrawal [42].
It has been reported that >65 % of JFM patients have a
current psychiatric disorder [10], and the exclusion of
patients with severe psychiatric comorbidities may have
limited enrollment in the milnacipran program. The
general under-recognition of JFM may have also contrib-
uted to the difficulty of recruiting patients into the mil-
nacipran program. Ongoing debates about how to define
JFM can lead to delays in diagnosis and treatment for
many patients [4], and some patients may not receive
early medical attention for their condition. The diagnosis
of JFM remains primarily symptom-based, and greater
awareness among healthcare professionals is needed in
order for patients to receive a more timely diagnosis. To
that end, data collected from the 116 patients who
entered the open-label period of the randomized
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the characteristics of adolescents who met the tender
point and symptom criteria for FM, as assessed using
the Yunus and Masi criteria [6], 1990 ACR criteria [7],
or both. Specifically, the large majority of patients in this
trial satisfied both sets of criteria; however, the Yunus
and Masi criteria identified an important minority of
patients (16.4 %) that were not identified by the ACR
criteria. It is unclear whether this group might differ
from patients satisfying the ACR criteria in response to
treatment.
Similar to findings in adults with FM [43–46], the ma-
jority of participants in the milnacipran program were
female, with mean baseline scores indicating substantial
pain severity, fatigue symptoms, and reduced quality of
life. Of the 116 patients who entered the open-label
period of the randomized withdrawal study, 84.5 % were
female. Mean baseline pain scores (>6 of 10) and PGIS
scores (4 of 7) suggest that patients generally had
moderate-to-severe symptoms prior to treatment. The
mean baseline score for the PedsQL Generic Core Scales
(55.4 for the total open-label population) was similar to
the patient-reported score found by the Outcomes Mea-
sures in Rheumatology (OMERACT) Fibromyalgia
Working Group in their validation study of this instru-
ment (55.9) [36]. In the OMERACT study, the PedsQL
Generic Core Scales was significantly lower in JFM pa-
tients than in pediatric cancer patients, rheumatology
patients, and healthy controls (all p <0.001), indicating
the negative impact of JFM on physical, psychosocial,
and emotional functioning. The mean baseline score for
the Multidimensional Fatigue Scale score was more se-
vere in the milnacipran program (45.3) than in the
OMERACT study (55.5), which emphasizes the import-
ance of identifying and managing fatigue-related symp-
toms in patients with JFM.
Baseline mean MASC and CDI scores in the open-
label population (Table 3) were somewhat higher (i.e.,
more severe) than normative scores found in a general
adolescent population [47], although the CDI score was
lower (i.e., less severe) than has been previously reported
in JFM patients [3]. The percentage of patients in the
milnacipran program with a history of depression
(16.4 %) or anxiety (9.5 %) was also lower than has been
previously reported in JFM [10]. These results are not
surprising since patients with severe or unstable psychi-
atric disorders were excluded from the milnacipran pro-
gram; similarly mild levels of depressive symptoms had
been found in milnacipran studies that also excluded adult
FM patients with severe psychiatric illness [22, 24, 25].
Other types of chronic conditions and pain-related
symptoms seen in the milnacipran program (Table 1)
were similar to those found in clinical studies of JFM
[2, 3, 6] and in survey studies of adult FM [43, 48].Interestingly, many of these symptoms (e.g., sleep dis-
order, irritable bowel syndrome, arthralgia, fatigue,
hypermobility syndrome, temporomandibular joint syn-
drome) were also less prevalent (<10 %) than expected.
Aside from the exclusion of patients with major psychi-
atric comorbidities, no compelling explanation can be
provided for these results. On the other hand, it should
be noted that >10 % of patients in this study did have a
history of asthma (23.3 %), drug hypersensitivity
(18.1 %), or seasonal allergy (16.4 %). It is difficult to
speculate why these conditions were so common in the
milnacipran JFM program, but research in adult FM
patients suggests that neuroendocrine abnormalities—
along with potential immunomodulatory effects of de-
creased serotonin levels on neuroendocrine systems
—may play a role in the clinical overlap between chronic
pain and inflammatory diseases [49, 50].
Low enrollment in the double-blind randomized with-
drawal phase of the initial study, which was terminated,
prevents interpretation of outcomes from that period.
However, the open-label phases of the milnacipran pro-
gram provide preliminary information about the poten-
tial effects of milnacipran in JFM. Mean changes in the
largest patient sample (i.e., the 116 patients who entered
the open-label period of the randomized study) and in
the sample with the longest duration of treatment (i.e.,
the 56 patients who entered the extension study and had
available outcome assessments) indicate that these pa-
tients, all of whom received open-label treatment with
milnacipran, reported improvements in multiple symp-
tom domains (Table 3 and Fig. 2). Although only 20
(17.2 %) of the 116 patients from the 8-week open-label
period of the initial study met the ≥50 % pain responder
criterion required for randomized withdrawal, 27.7 %
reached a clinically meaningful threshold of ≥30 % pain
improvement [39]. While no direct comparisons can be
made due to marked differences in study design, results
from the 12-week double-blind study of adult FM
showed that 44.6 % of patients had ≥30 % pain improve-
ment with milnacipran 100 mg/day, compared to 30.6 %
in the placebo group (p < 0.001) [22].
Improvements in quality of life should also be noted since
restored functioning is often considered to be as important
as pain reduction in managing JFM [51]. No minimal clin-
ically important differences for PedsQL have been estab-
lished for JFM, but studies in other chronic childhood
conditions suggest that a 4.5- to 6-point increase may
reflect clinically relevant improvement [52, 53]. After open-
label treatment in the randomized withdrawal study and
during the extension the study, mean score changes in the
PedsQL Generic Core Scales matched or exceeded these
suggested thresholds. Improvements in this outcome meas-
ure, which encompasses various functional domains (i.e.,
physical, emotional, social, and school-related), along with
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patients with JFM may experience clinical benefits with
milnacipran, particularly after several months of treatment.
Evaluating the safety and tolerability of milnacipran in
JFM was an important aspect of this program, and it
should be noted that dosing was based on tolerability.
Overall, the tolerability profile in these patients (Table 4)
was similar to the profile seen in adults with FM [31],
with nausea, headache, vomiting, headache, and dizzi-
ness being the most commonly reported TEAEs after
treatment was initiated in the open-label period of the
randomized withdrawal study. The percentage of pa-
tients who discontinued this open-label period due to an
AE (7 %) was lower than in placebo-controlled, fixed-
dose studies of adult FM (23 % for the 100 mg/day dos-
age [31]); in both populations, however, nausea was the
most common AE associated with discontinuation. The
mean increases in blood pressure and heart rate found
in the JFM population (Table 5) were also generally simi-
lar to the increases found in adults with FM [31]. These
parameters were generally found to decrease after dis-
continuation of milnacipran in adults [54]. However, the
long-term implications of milnacipran’s effects on blood
pressure and heart rate are unknown.
Designing and conducting clinical trials in pediatric
populations continues to be a challenge in many thera-
peutic areas [55]. In the milnacipran JFM program, the
rationale for including an initial open-label treatment
period was that it might induce more patients to enroll.
However, this approach estimated that >300 patients
would be needed to detect statistical significance in the
double-blind withdrawal phase, which may have been
too difficult a task given the general under-recognition
of JFM [4]. In retrospect, it might have been easier to
implement a more typical placebo-controlled, parallel-
group design that would have required fewer patients.
More flexible eligibility criteria might also have helped
to increase enrollment—for example, allowing patients
with stable mild-to-moderate major depression or pa-
tients requiring concomitant medications such as anti-
convulsants for migraine. Within the study itself, a less
onerous study visit schedule and simpler data collection
techniques (e.g., more use of interactive web/voice re-
sponse systems) might have helped to accommodate an
adolescent population that may have been busy with
competing interests such as school, social life, and extra-
curricular activities. Finally, although various tools were
made available to Investigators to help recruit patients
into the milnacipran program (e.g., website and mobile
applications with study information and basic eligibility
criteria, an online campaign to direct general web
searches for JFM to the milnacipran program, press re-
leases, support for print/radio/television advertising),
continued efforts are needed to increase the generalawareness of JFM. Such efforts could include reaching
out to women with FM who might have at-risk children
and reassuring them about clinical research in children,
public service announcements about JFM, advertising
with adult FM support groups, and outreach/education
to pediatric rheumatologists.
The main limitations of the JFM milnacipran program
have been discussed above, most notably with regards to
study design, exclusion criteria, randomization criteria,
and study termination due to low recruitment. Continued
evaluation of the safety and efficacy of milnacipran and
other pharmacotherapies in this patient population is war-
ranted. Areas of potential interest include identifying pre-
dictors of pain response in JFM patients, exploring the
relationship between pain relief and improvements in
other symptom domains, and evaluating the effects of
adjunctive nonpharmacologic therapies such as CBT and
exercise.Conclusions
The milnacipran program showed that recruiting ado-
lescent patients into a JFM treatment study can be a
challenging proposition. Despite intensive recruitment
efforts and the implementation of a randomized with-
drawal paradigm that allowed patients to start by enter-
ing an open-label treatment period, only 171 patients
from 47 study centers in the United States were
screened for eligibility. Of these, 116 entered into the
open-label period of the randomized withdrawal study,
and only 20 patients were randomized for double-blind
withdrawal. The ACR criteria for FM identified most
patients with JFM in this program, but the Yunus and
Masi criteria identified an additional 16.4 % of patients.
Aside from exhibiting less severe depressive and anxiety
symptoms due to eligibility criteria, the overall profile
of these adolescent patients was not largely different
from the profile of adult FM patients. Milnacipran was
generally well tolerated, with more than two-thirds of
the patients tolerating the maximum allowed dose of
100 mg/day and a side-effect profile similar to that seen
in adults [31]. Results with open-label milnacipran
treatment of JFM provided preliminary data that this
medication may improve symptoms and function in
some patients with JFM, but the pain responder rate
was relatively low and controlled studies are needed to
confirm these findings.Additional file
Additional file 1: Supplementary information and results. This file
includes the following: eligibility criteria at screening; timeline of
assessments; potentially clinically significant changes in vital signs,
electrocardiograms, and laboratory tests; and pain responders in the
Arnold et al. Pediatric Rheumatology  (2015) 13:27 Page 13 of 14extension study, defined as patients with ≥30 % pain improvement from
baseline of the randomized withdrawal study.
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